trending Market Intelligence /marketintelligence/en/news-insights/trending/B6Dws9ge59QlVP_z65z3Tw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Jazz Pharmaceuticals acquires neurological drug developer Cavion

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Jazz Pharmaceuticals acquires neurological drug developer Cavion

Jazz Pharmaceuticals PLC acquired Cavion Inc. for $52.5 million up front.

The deal was carried out through the merger of Cavion and a Jazz Pharmaceutical subsidiary.

Charlottesville, Va.-based Cavion, which develops therapies for chronic and rare neurological diseases, is eligible to receive additional payments of up to $260 million, subject to achievement of certain clinical, regulatory and commercial milestones.

The company's lead drug candidate, CX-8998, is being investigated as a potential treatment for essential tremor, a neurological disorder characterized by involuntary and rhythmic shaking, mostly of hands.

Jazz Pharmaceuticals said the transaction and the addition of CX-8998 further diversifies its pipeline and product portfolio.

In addition, Cavion appointed Fortis Advisors LLC as shareholder representative. The company's financial adviser for the deal was MTS Health Partners LP, with Cooley LLP as legal adviser and Pilot Health Advisors LLC as strategic adviser.

Hogan Lovells was Jazz Pharmaceuticals' legal adviser for the acquisition.